GlassScriptPhysician profile
Daniel J Addanki
NPI 1023281342
$54,492.57
in general payments reported to CMS, 2019-2025
38 companies · $41K in 2025
The $41K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $748 · 2021: $2,099 · 2022: $3,125 · 2023: $2,914 · 2024: $4,263 · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $40K · Food and Beverage: $6,404 · Travel and Lodging: $848 · Education: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $39,933.37 |
| Food and Beverage | $6,403.85 |
| Travel and Lodging | $847.75 |
| Education | $708.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $41,256.12 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,955.78 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $1,708.57 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $1,021.03 | 2019-2025 | Jynarque, Voyxact |
| Aurinia Pharma U.S., INC. | $874.83 | 2021-2025 | Lupkynis |
| Amgen INC. | $759.50 | 2020-2025 | Tavneos, Parsabiv, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $662.13 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $575.06 | 2020-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $470.91 | 2020-2025 | Velphoro, Velphoro, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.46 | 2021-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $422.01 | 2022-2025 | Tarpeyo |
| Novo Nordisk INC | $382.93 | 2020-2025 | Ozempic, Rybelsus |
| Travere Therapeutics, INC. | $360.95 | 2020-2025 | Thiola |
| Glaxosmithkline, LLC. | $348.53 | 2021-2024 | Benlysta, Jesduvroq, Nucala |
| Mallinckrodt Hospital Products INC. | $340.95 | 2020-2024 | Acthar |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $204.19 | 2023-2025 | Jardiance, Zepbound |
| Akebia Therapeutics INC | $179.82 | 2021-2022 | |
| Medtronic, INC. | $159.98 | 2025 | Symplicity G3 |
| Genzyme Corporation | $145.80 | 2021-2024 | |
| Daiichi Sankyo INC. | $141.46 | 2020-2022 | |
| W. L. Gore & Associates, INC. | $139.64 | 2023 | Gore Viabahn Endoprosthesis |
| Pfizer INC. | $117.57 | 2021-2025 | |
| Amarin Pharma, INC. | $110.73 | 2020-2022 | |
| Ardelyx, INC. | $90.55 | 2024-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $90.14 | 2021-2024 | Ultomiris, Strensiq |
| Ani Pharmaceuticals, INC. | $77.96 | 2022-2023 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $74.49 | 2023 | Krystexxa |
| Ultragenyx Pharmaceutical INC. | $65.62 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $58.71 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $55.56 | 2020-2021 | |
| Kyowa Kirin, INC. | $46.60 | 2024 | Crysvita |
| Alnylam Pharmaceuticals INC. | $42.34 | 2023-2024 | Givlaari |
| Merck Sharp & Dohme LLC | $35.16 | 2023 | Verquvo |
| Abbvie INC. | $27.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.00 | 2021 | |
| Azurity Pharmaceuticals, INC. | $16.83 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.60 | 2021 | |
| Biogen, INC. | $14.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Addanki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.